新辅助化疗完成至术后辅助化疗开始的时间间隔对晚期卵巢癌患者生存的影响
该回顾性研究纳入2006至2016年在Yonsei癌症医院接受新辅助化疗的220例病理确诊上皮性卵巢癌患者,分析从新辅助化疗完成(涵盖中间性减瘤术)至术后辅助化疗开始的时间间隔与生存的关系。中位间隔42天(范围16-178天),间隔>42天组无进展生存和总生存均更差(P=0.039和0.005)。作者认为该间隔可能影响生存,缩短间隔或可改善结局。
要点
- 中位时间间隔为42天(范围16-178天)。
- 间隔>42天组无进展生存和总生存均更差(P=0.039和0.005)。
- 按四分位分组,间隔越长复发和死亡风险越高(趋势P=0.006和<0.001)。
核心结论
- 从新辅助化疗完成至术后辅助化疗开始的时间间隔似乎影响生存,努力缩短该间隔可能改善接受新辅助化疗的卵巢癌患者结局。
研究设计与样本
- 回顾性研究,纳入2006至2016年在Yonsei癌症医院接受新辅助化疗的220例病理确诊上皮性卵巢癌患者。
- 时间间隔定义为从新辅助化疗完成、跨越中间性减瘤术、至术后辅助化疗开始的时间。
主要发现
- 中位时间间隔为42天(范围16-178天);103例(53.1%)在42天内开始术后辅助化疗,91例(46.9%)在42天后开始。
- 两组患者特征无显著差异。
- Kaplan-Meier分析显示间隔>42天组无进展生存和总生存均更差(P=0.039和0.005)。
- 多因素分析中,间隔较长组无进展生存的风险比为1.41(95%CI 0.98-2.03,未达统计学显著),总生存的风险比为2.03(95%CI 1.16-3.54)。
- 按时间间隔四分位分组(≤37、38-42、43-50和>50天),间隔越长复发和死亡风险越高(趋势P=0.006和<0.001)。
临床怎么用
- 作者认为从新辅助化疗完成至术后辅助化疗开始的时间间隔似乎影响生存,努力缩短该间隔可能改善接受新辅助化疗的卵巢癌患者结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the relationship of the time interval from the completion of neoadjuvant chemotherapy (NAC) to the initiation of postoperative adjuvant chemotherapy (POAC) with the survival outcomes in patients with ovarian cancer. METHODS: We retrospectively investigated 220 patients with pathologically confirmed epithelial ovarian cancer who received NAC at Yonsei Cancer Hospital between 2006 and 2016. The time interval was defined as the period from the completion of NAC, spanning interval debulking surgery (IDS), to the initiation of POAC. RESULTS: The median time interval was 42 (range 16-178) days; 103 patients (53.1%) received POAC within 42days after NAC while 91 patients (46.9%) received it after 42days. There were no significant differences in patient characteristics between these 2 groups. Kaplan-Meier analysis showed that patients with longer time intervals (>42days) had poorer progression-free survival and overall survival (P=0.039 and 0.005, respectively). In the multivariate analysis, patients with longer time intervals had significantly poorer progression-free (hazard ratio, 1.41; 95% confidence interval, 0.98-2.03; not significant) and overall survivals (hazard ratio, 2.03; 95% confidence interval, 1.16-3.54). When the patients were categorized according to time interval quartiles (≤37, 38-42, 43-50, and >50days), longer time intervals were associated with higher risks of recurrence and death (P for trend: 0.006 and <0.001, respectively). CONCLUSION: The time interval from the completion of NAC to the initiation of POAC appears to influence survival. Efforts to reduce the time interval might improve the outcomes in ovarian cancer patients undergoing NAC.
引用
- Lee YJ, Chung YS, Lee JY, et al. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. Gynecol Oncol. 2017. PMID: 29174056. doi:10.1016/j.ygyno.2017.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。